Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?

Hans Slabbynck, Johan Clukers, Daniella Galdermans

Source: Eur Respir J, 55 (1) 1902028; 10.1183/13993003.02028-2019
Journal Issue: January
Disease area: Pulmonary vascular diseases, Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Hans Slabbynck, Johan Clukers, Daniella Galdermans. Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?. Eur Respir J, 55 (1) 1902028; 10.1183/13993003.02028-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Risk factors for recurrences in patients with idiopathic pulmonary embolism after withdrawal of long-term anticoagulation
Source: Eur Respir J 2006; 28: Suppl. 50, 44s
Year: 2006

Mortality and recurrence during a follow-up of 2 years of pulmonary embolism: Role of anticoagulant therapy
Source: Annual Congress 2010 - Pulmonary embolism
Year: 2010

The incidence of venous thromboembolism recurrence in patients after first episode acute pulmonary embolism and related risk factors
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012


Should thrombolysis and sildenafil be given in the acute management of patients with large pulmonary embolism? An assessment of the short and long-term outcomes.
Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment
Year: 2019


Risks of pulmonary thromboembolism associated with ambulatory management of clinically proven deep vein thrombosis
Source: Annual Congress 2005 - News about pulmonary embolism
Year: 2005


Early discharge of patients with pulmonary embolism: feasibility of domicillary anticoagulation
Source: Eur Respir J 2003; 22: Suppl. 45, 219s
Year: 2003

The outcome of anticoagulation alone therapy for patients with submassive pulmonary embolism
Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Year: 2019


Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism
Source: Eur Respir J 2013; 41: 588-592
Year: 2013



Pulmonary angioplasty vs exclusive medical treatment in inoperable chronic thromboembolic hypertension–initial outcomes from a pulmonary hypertension centre
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020


Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004


Presence of bronchopulmonary shunting is an independent risk factor for recurrence of hemoptysis following bronchial artery embolization in younger patients with bronchiectasis: a long-term outcome
Source: International Congress 2019 – Highlights in lung function and chronic cough
Year: 2019

Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review
Source: Eur Respir J 2009; 33: 1148-1155
Year: 2009



Recommended uses for indefinite secondary prophylaxis in patients with pulmonary embolism
Source: Eur Respir J 2006; 28: Suppl. 50, 402s
Year: 2006

Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment
Source: Eur Respir J 2016; 48: 1369-1376
Year: 2016



Efficacy of a 12 months oral sildenafil treatment in patients with severe pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 660s
Year: 2006

A risk score of adverse short-term clinical outcomes in patients with acute pulmonary embolism (PE)
Source: Eur Respir J 2005; 26: Suppl. 49, 271s
Year: 2005

A case-control study on direct oral anticoagulants versus warfarin for acute pulmonary embolism in obese patients
Source: Virtual Congress 2021 – Insights into pulmonary embolism
Year: 2021



Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli
Source: ERJ Open Res, 7 (1) 00554-2020; 10.1183/23120541.00554-2020
Year: 2021



The evaluation of medication adherence in patients with pulmonary thromboembolism
Source: International Congress 2018 – Acute pulmonary embolism: from diagnosis to treatment
Year: 2018



Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy
Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension
Year: 2019